Early access
Sign in
Taking people in Hong KongNo phase

Checking non-invasive tests to predict outcomes in liver cancer patients

Tests liver scans and throat scopes in adults with liver cancer and cirrhosis.

Key facts

Who runs it
Chinese University of Hong Kong
Where
Hong Kong, Hong KongSee the site
Trial code
Registry title
Non-invasive Assessment for Outcome Prediction in Patients With Hepatocellular Carcinoma
Status
Recruiting
People taking part
159 people, planned
Started
4 Nov 2024
Expected to end
Dec 2030
Type of study
Observational
Treatments tested
  • transient elastography and oesophagogastroduodenoscopy
Record updated
20 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with long-term liver disease and a first liver cancer (HCC) who are planned for treatment meant to remove all of the cancer.

Age
18 years or older
Sex
Women and men can join.
Disease stage
Hepatocellular carcinoma (HCC) seen on typical scan features or biopsy, planned for surgery or local ablation (heat or similar treatment applied to the tumour). Child's B cirrhosis without complications can join.
Earlier treatment
People with a past HCC, or whose current HCC is a return of a treated HCC, cannot join. People who had or are planned for a liver transplant cannot join.

Main reasons for not taking part

  • Current or past decompensated cirrhosis (Child's C, ascites, variceal bleeding, hepatic encephalopathy, hepatorenal syndrome)
  • Past HCC, or a second new HCC after a first one
  • Liver tumour that did not start in the liver
  • No spleen or past spleen removal
  • Pregnancy

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Aged 18 or above
  • Known chronic liver disease(s)
  • HCC for curative-intent treatment (defined by HCC diagnosed with typical radiological features or histology, and planned for surgical resection or local ablative therapy as a curative-intent treatment)

Who cannot take part

  • Current or history of decompensated liver cirrhosis (i.e. Child's C cirrhosis, prior decompensating events such as ascites, variceal bleeding, hepatic encephalopathy and hepatorenal syndrome); o Child's B cirrhosis without decompensating events is not excluded
  • Past history of HCC (ie. The current HCC is a recurrence of priorly treated HCC or a second de novo HCC after previous first HCC)
  • History of liver transplantation or plan for liver transplantation as the modality of curative-intent HCC treatment
  • Asplenism or history of splenectomy
  • Contraindication to OGD (eg. Intestinal perforation of obstruction)
  • Serious medical illness with limited life expectancy of less than 6 months
  • Non-primary liver tumour (such as secondary liver tumour due to metastasis from another distant primary tumour)
  • Pregnancy
  • Unable to obtain or refusal of informed consent from patient

Where in Hong Kong

  • Prince of Wales HospitalHong Kong, Hong KongContact: Jimmy CT Lai, MB ChBTaking people

About the trial

What the trial wants to find out

This is a single-centre, prospective cohort study. Consecutive patients with compensated liver disease and hepatocellular carcinoma (HCC) for curative-intent treatment will be invited to this study. The study follow-up duration will be five years. The primary outcome is the composite of incident high-risk varices, hepatic decompensation and liver-related mortality. The participants will undergo transient elastography at baseline and then half-yearly post-HCC curative treatment; and oesophagogastroduodenoscopy (OGD) at baseline and then at year 1, 3 and 5 post-HCC curative treatment. Clinical assessments and laboratory tests will also be done at baseline and every 6 months until year 5 to identify any clinical events.

The group in the trial

  • Patients with hepatocellular carcinoma

    Adult patients with known chronic liver disease and hepatocellular carcinoma planning for curative-intent treatment

    Treatment: transient elastography and oesophagogastroduodenoscopy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Validation of Baveno VII Criteria and Spleen Stiffness Measurement on Outcome Prediction in Patients With Hepatocellular Carcinoma
Plain-language title
Checking non-invasive tests to predict outcomes in liver cancer patientsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
20 October 2026